Trial Profile

Phase 1/2 Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; ONO 4578 (Primary)
Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

15 Mar 2021 Status changed from recruiting to completed.
31 Jan 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record. (2020-12-29)
14 Nov 2020 This trial has been Discontinued in Italy, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com